Cybin announces publication of sponsored feasibility study validating kernel's flow1 neuroimaging technology measuring psychedelic effects on the brain

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, commends kernel, a leader in non-invasive neuroimaging, on their publication titled "measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using td-fnirs" in the journal scientific reports from the nature.
CYBN Ratings Summary
CYBN Quant Ranking